scholarly journals Posterior reversible encephalopathy syndrome (PRES) triggered by blood transfusion in a patient with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS)

2007 ◽  
Vol 40 (8) ◽  
pp. 655-661
Author(s):  
Yoshikuni Nagayama ◽  
Shigeki Iwasaki ◽  
Eri Kawashima ◽  
Ashio Yoshimura
Keyword(s):  
Blood Transfusion ◽  
Hemolytic Uremic Syndrome ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Posterior Reversible Encephalopathy Syndrome ◽  
Thrombocytopenic Purpura ◽  
Posterior Reversible Encephalopathy ◽  
Uremic Syndrome ◽  
Reversible Encephalopathy

scholarly journals An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment

2018 ◽  
Vol 10 (3) ◽  
Author(s):  
Serife Solmaz Medeni ◽  
Sinem Namdaroglu ◽  
Tugba Cetintepe ◽  
Can Ozlu ◽  
Funda Tasli ◽  
...  
Keyword(s):  
Hemolytic Uremic Syndrome ◽  
Plasma Exchange ◽  
Posterior Reversible Encephalopathy Syndrome ◽  
Complement Activation ◽  
Late Onset ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Neurological Involvement ◽  
Posterior Reversible Encephalopathy ◽  
Uremic Syndrome ◽  
Reversible Encephalopathy

Atypical hemolytic uremic syndrome is a rare and progressive disease caused by uncontrolled alternative complement activation. Dysregulatıon of the complement activation results in thrombotic microangiopathy and multiorgan damage. A 29-yearold woman who was admitted with complaints of vomiting and headache was detected to have acute renal failure with microangiopathic hemolytic anemia (MAHA). After the diagnosis of atypical hemolytic uremic syndrome (aHUS), she was treated with plasma exchange (PE) and hemodialysis (HD). She has experienced hypertensionrelated posterior reversible encephalopathy syndrome (PRES) at the second plasma exchange. She was initiated on eculizumab therapy because of no response to PE on the 34th days. Her renal functions progressively improved with eculizumab treatment. Dependence on dialysis was over by the 4th month. Dialysis free-serum Creatinine level was 2.2 mg/dL [glomerular filtration rate (e-GFR): 30 mL/min/1.73 m2] after 24 months. Neurological involvement (PRES, etc.) is the most common extrarenal complication and a major cause of mortality and morbidity from aHUS. More importantly, we showed that renal recovery may be obtained following late-onset eculizumab treatment in patient with aHUS after a long dependence on hemodialysis.

scholarly journals Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS)

2004 ◽  
Vol 66 (3) ◽  
pp. 955-958 ◽  
Author(s):  
Christoph Licht ◽  
Ludwig Stapenhorst ◽  
Thorsten Simon ◽  
Ulrich Budde ◽  
Reinhard Schneppenheim ◽  
...  
Keyword(s):  
Hemolytic Uremic Syndrome ◽  
Thrombotic Thrombocytopenic Purpura ◽  
Gene Mutations ◽  
Thrombocytopenic Purpura ◽  
Uremic Syndrome
Sign in / Sign up

Export Citation Format

Share Document